Literature DB >> 3919529

Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment.

A L Hulting, C Muhr, P O Lundberg, S Werner.   

Abstract

Thirty-seven men with prolactin (PRL) producing pituitary adenomas were studied to elucidate if patient's delay might cause the predominance of large tumours in men as compared to women in whom microadenomas predominate. We found two clinical subgroups; one presented with short duration of symptoms, dominated by local signs from the growth of notably large tumours, the other exhibited a long history of disease with hypogonadism as the dominating symptom. There was a correlation between tumour size and PRL levels. The age at the time of diagnosis showed no correlation to duration of symptoms, size of adenoma or PRL levels. Four patients with small adenomas, moderate hyperprolactinemia and short duration of symptoms showed signs of hypergonadotropic hypogonadism. Surgery or irradiation, performed in 14 patients, did not normalize PRL levels. Bromocriptine was equally beneficial in the two clinical subgroups, improving clinical symptoms and normalizing PRL levels in all but three patients. The study shows that the predominance of large tumours in men does not depend on patient's or doctor's delay, but on a high frequency of presumably rapidly growing PRL producing tumours. In the majority of patients, these tumours do not give signs of hypogonadism before the tumour is revealed by local signs of tumour growth.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919529     DOI: 10.1111/j.0954-6820.1985.tb01642.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  8 in total

1.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Authors:  D Kojo Hamilton; Mary Lee Vance; Paul T Boulos; Edward R Laws
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.

Authors:  Mussa H Almalki; Badurudeen Buhary; Saad Alzahrani; Fahad Alshahrani; Safia Alsherbeni; Ghada Alhowsawi; Naji Aljohani
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 4.  Hyperprolactinemia in men: clinical and biochemical features and response to treatment.

Authors:  Michele De Rosa; Stefano Zarrilli; Antonella Di Sarno; Nicola Milano; Maria Gaccione; Bartolomeo Boggia; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

5.  Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.

Authors:  Ilan Shimon; Carlos Benbassat; Gloria Tzvetov; Simona Grozinsky-Glasberg
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

6.  Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).

Authors:  M Berezin; I Shimon; M Hadani
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

7.  Sexual function in women with hypothalamo-pituitary disorders.

Authors:  B Hulter; P O Lundberg
Journal:  Arch Sex Behav       Date:  1994-04

8.  Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.

Authors:  Eun-Hee Cho; Sang Ah Lee; Ji Youn Chung; Eun Hee Koh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Min-Seon Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.